Drug intelligence / Profile preview

E09

Development stage: Discontinued
Modality: Small Molecules
Administration: Intravenous

Overview

E09 is a bioreductive alkylating agent developed as a chemotherapy drug. It was assessed in a phase II trial as second-line treatment for breast cancer patients and as first-line treatment for patients with gastric, pancreatic, and colorectal cancer. The drug was administered as a 5-minute intravenous infusion at a weekly dose of 12 mg/m2. While generally well-tolerated, with common side effects including nausea, vomiting, and reversible proteinuria, E09 did not demonstrate antitumor activity in the tumor types studied at the tested dose and schedule.

Targets

DNA

Beyond the preview

Go deeper on E09.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on E09.

Explore the full profile